Literature DB >> 23448267

Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1.

Jesús R Medina1.   

Abstract

3-Phosphoinositide-dependent protein kinase 1 (PDK1) is a protein target that has generated considerable interest in both academia and the pharmaceutical industry. PDK1 is responsible for regulating the activity of related kinases in the AGC kinase family, including AKT, by phosphorylating a specific threonine or serine residue within the activation loop which is critical for kinase activation. Many of the kinases activated by PDK1 regulate cellular process such as cell survival, differentiation, growth, and protein expression. Although significant work has been done to understand the role of PDK1 function in cells, recently discovered potent and selective small molecule PDK1 inhibitors are providing a unique opportunity to further dissect PDK1 function and predict the pharmacological consequences of PDK1 inhibition. This Miniperspective reviews the discovery of these selective PDK1 inhibitors and highlights their value in cellular studies, the understanding of PDK1 biology, and the impact on the therapeutic potential of PDK1 inhibition in cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23448267     DOI: 10.1021/jm4000227

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer.

Authors:  Lihong Han; Guoxiu Zhang; Nali Zhang; Haiyan Li; Yanyan Liu; Aiguo Fu; Youguang Zheng
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

2.  A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.

Authors:  T Justin Rettenmaier; Jack D Sadowsky; Nathan D Thomsen; Steven C Chen; Allison K Doak; Michelle R Arkin; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-17       Impact factor: 11.205

3.  Influence of CHIEF pathway genes on gene expression: a pathway approach to functionality.

Authors:  Martha L Slattery; Abbie Lundgreen; Lila E Mullany; Rosalind B Penney; Roger K Wolff
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

Review 4.  Non-kinase targets of protein kinase inhibitors.

Authors:  Lenka Munoz
Journal:  Nat Rev Drug Discov       Date:  2017-03-10       Impact factor: 84.694

5.  Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Authors:  Valerie M Jansen; Neil E Bhola; Joshua A Bauer; Luigi Formisano; Kyung-Min Lee; Katherine E Hutchinson; Agnieszka K Witkiewicz; Preston D Moore; Mónica Valéria Estrada; Violeta Sánchez; Paula G Ericsson; Melinda E Sanders; Paula R Pohlmann; Michael J Pishvaian; David A Riddle; Teresa C Dugger; Wenyi Wei; Erik S Knudsen; Carlos L Arteaga
Journal:  Cancer Res       Date:  2017-03-01       Impact factor: 12.701

Review 6.  Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.

Authors:  Pau Castel; Eneda Toska; Zachary S Zumsteg; F Javier Carmona; Moshe Elkabets; Ana Bosch; Maurizio Scaltriti
Journal:  Mol Cell Oncol       Date:  2014-10-29

7.  Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking.

Authors:  T Justin Rettenmaier; Hao Fan; Joel Karpiak; Allison Doak; Andrej Sali; Brian K Shoichet; James A Wells
Journal:  J Med Chem       Date:  2015-10-12       Impact factor: 7.446

8.  The 3-phosphoinositide-dependent protein kinase 1 is an essential upstream activator of protein kinase A in malaria parasites.

Authors:  Eva Hitz; Natalie Wiedemar; Armin Passecker; Beatriz A S Graça; Christian Scheurer; Sergio Wittlin; Nicolas M B Brancucci; Ioannis Vakonakis; Pascal Mäser; Till S Voss
Journal:  PLoS Biol       Date:  2021-12-08       Impact factor: 8.029

Review 9.  3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.

Authors:  Chanse Fyffe; Marco Falasca
Journal:  Cancer Manag Res       Date:  2013-08-23       Impact factor: 3.989

10.  Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.

Authors:  M Signore; F Pelacchi; S di Martino; D Runci; M Biffoni; S Giannetti; L Morgante; M De Majo; E F Petricoin; L Stancato; L M Larocca; R De Maria; R Pallini; L Ricci-Vitiani
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.